Eli Lilly director Sulzberger granted stock at $1,164.89

Lilly director Gabrielle Sulzberger received a small deferred stock-unit award tied to cash compensation, raising her directly held equivalent common shares to about 3,012.

Rhea-AI Filing Summary

ELI LILLY & Co (LLY) reported that director Gabrielle Sulzberger acquired a small additional position in common stock through a compensation-related award. On September 21, 2026, she received 4.2565 shares credited at $1,164.89 per share, bringing her directly held total to 3,012.4473 shares. Per her election, this award has been deferred into stock units under the Lilly Directors' Deferral Plan and will be settled in common shares after her separation from service.

Insider Trade Summary

Grant/Award: 4.2565 shares

Grant/Award 1 txn

Insider Sulzberger Gabrielle

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	4.2565	$1,164.89	$5K

Holdings After Transaction: Common Stock — 3,012.4473 shares (Direct)

Footnotes (1)

1. F1. At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service.

Key Figures

Shares acquired: 4.2565 shares Grant price per share: $1,164.89 per share Total shares following transaction: 3,012.4473 shares +1 more

4 metrics

Shares acquired 4.2565 shares Grant, award, or other acquisition on September 21, 2026

Grant price per share $1,164.89 per share Value used for the September 21, 2026 stock award

Total shares following transaction 3,012.4473 shares Directly held Eli Lilly common stock after the award

Transaction date September 21, 2026 Date of compensation-related stock award to director

Key Terms

Lilly Directors' Deferral Plan, stock units, separation from service

3 terms

Lilly Directors' Deferral Plan financial

"deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan"

stock units financial

"deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan"

Stock units are individual pieces of ownership in a company, like slices of a pie that together make up the whole business. They matter to investors because each unit represents a claim on the company’s assets, profits and sometimes voting power, and changes in the number or value of these units affect ownership percentages, potential dividends and share dilution — all of which influence an investment’s worth.

separation from service financial

"will be settled in shares of common stock following the reporting person's separation from service"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did LLY disclose for director Gabrielle Sulzberger?

LLY disclosed that director Gabrielle Sulzberger acquired 4.2565 shares of Eli Lilly common stock on September 21, 2026 as a compensation-related grant that was deferred into stock units under the Lilly Directors' Deferral Plan.

At what price was the latest Eli Lilly (LLY) director stock award recorded?

The compensation-related stock award to director Gabrielle Sulzberger was recorded at $1,164.89 per share, applied to 4.2565 shares of Eli Lilly common stock, according to the Form 4 disclosure.

How many Eli Lilly (LLY) shares does Gabrielle Sulzberger hold after the reported transaction?

After the September 21, 2026 award, director Gabrielle Sulzberger is reported as holding 3,012.4473 shares of Eli Lilly common stock on a direct basis, including the newly credited deferred stock units.

Was the LLY director award made under a Rule 10b5-1 trading plan?

No. The Form 4 indicates the Rule 10b5-1 checkbox is not affirmed, and the transaction is described as a grant, award, or other acquisition tied to director compensation rather than a trading-plan sale or purchase.

How will Gabrielle Sulzberger’s deferred LLY stock units be settled?

The filing states that the shares acquired have been deferred as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following Gabrielle Sulzberger’s separation from service as a director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/22/2026 - 04:18 PM Accepted by SEC EDGAR 09/22/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sulzberger Gabrielle

(Last) (First) (Middle)

LILLY CORPORATE CENTER

(Street)

INDIANAPOLIS INDIANA 46285

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ELI LILLY & Co [ LLY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/21/2026		A		4.2565(1)	A	$1,164.89	3,012.4473	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service.

Remarks:

	/s/ Christopher Anderson for Gabrielle Sulzberger, pursuant to authorization on file	09/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)